The AVID trial: Evidence based or randomized control trials-is the AVID study too late?

American Journal of Cardiology

Volumn 80, Issue 2, 1997, Pages 194-197

  Josephson, Mark E ^a   Nisam, Seah ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; SOTALOL;

CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEFIBRILLATOR; DRUG EFFICACY; EDITORIAL; HEART ARRHYTHMIA; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION;

EID: 0030746242     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00341-X     Document Type: Article

References (36)

1. AVID Trial Executive Committee. Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? Am J Cardiol 1997; 79:661-663.
2. Josephson M, Nisam S. Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? Am J Cardiol 1996;77:859-863.
3. Fogoros R. An AVID dissent [editorial]. PACE 1994;17:1707-1710.
4. Singer I. Letter to the editor. PACE 1994;17:260-262.
5. Mower M. Letter to the editor. PACE 1994;17:258-260.
6. Fogoros R. Impact of the implantable defibrillator on mortality: the axiom of overall implantable cardioverter-defibrillator survival. Am J Cardiol 1996;78(suppl 5A):57-61.
7. Singer I. Can the AVID trial provide meaningful answers. J Interven Cardiol 1996;9:425-428.
8. Estes M. Clinical strategies for use of the implantable cardioverter defibrillator: the impact of current trials. PACE 1996;19:1011-1015.
9. Lehmann M, Steinman RT, Schuger CD, Jackson K. The automatic implantable cardioverter defibrillator as antiarrhythmic treatment modality of choice for survivors of cardiac arrest unrelated to acute myocardial infarction. Am J Cardiol 1988;62:803-805.
10. Akhtar M, Avitall B, Jazayeri M, Tchou P, Troup P, Sra J, Axtel K. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients. Circulation 1992;85(suppl I):I-131-I-139.
11. Saksena S, Madan N, Lewis C. Implantable cardioverter-defibrillators are preferable to drugs a primary therapy in sustained ventricular tachyarrhythmias. Prog Cardiovasc Dis 1996;38:445-454.
12. Böcker D, Block M, Borggrefe M, Breithardt G. Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J 1997;18:26-30.
13. Powell A, Fuchs T, Finkelstein DM, Garan H, Cannom DS, McGovern BA, Kelly E, Vlahakes GJ, Torchiana DF, Ruskin JN. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-1092.
14. Fogoros R, Fiedler S, Elson J. The automatic implantable cardioverter defibrillator in drug-refractory ventricular arrhythmias. Ann Intern Med 1987;107:635-641.
15. Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, Franklin J, Scheinman MM, Griffin JC. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992;69:889-903.
16. Böcker E, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996;94:151-157.
17. Wever EF, Hauer RN, Van Capelle FL, Tijssen JG, Crijins HJ, Algra A, Weisfeld AC, Bakker PF, Robles de Medina EO. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-2203.
18. Moss A, Hall J, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M, for the MADIT Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Engl J Med 1996;335:1933-1940.
19. Singh S, Fletcher R, Fisher S, Singh B, Lewis D, Deedwania P, Massie B, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (STAT-CHF). Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
20. Waldo A, Camm J, deRuyter H, Friedman P, MacNeil D, Pauls J, Pitt B, Pratt C, Schwartz P, Veltri E, for the SWORD Investigators. Effect of d-l sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996:348:7-12.
21. Julian D, Camm J, Frangin G, Janse M, Munoz A, Schwartz P, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
22. Greene L, CASCADE Investigators. Cardiac arrest in Seattle: conventional versus amiodarone drug evaluation: the Cascade Study. Am J Cardiol 1991;67:578-584.
23. Mason J, on behalf of the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
24. Block M, Breithardt. Long-term follow-up and clinical results of implantable cardioverter-defibrillators. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders, 1995:1412-1425.
25. Bardy G, Hofer B, Johnson G, Kudenchuk P, Poole J, Dolack L, Gleva M, Mitchell R, Kelso D. Implantable transvenous cardioverter defibrillators. Circulation 1993;87:1152-1168.
26. Summary of safety and effectiveness data for the CPI Endotak lead system. Premarket Approval (PMA) application to U.S. Food and Drug Administration, 1993.
27. Summary of safety and effectiveness data for the Medtronic Transvene lead system premarket approval (PMA) application to U.S. Food and Drug Administration, number p. 920015, 1993.
28. Block M, and the European P2 Investigators. Combination of endocardial leads with a new ICD capable of biphasic shocks - first results of a multicenter study. PACE 1993;16:874A.
29. Pacifico A, Wheelan K, Nasir N, Wells P, Doyle T, Johnson S, Henry P. Long-term follow-up of cardioverter-defibrillator implanted under conscious sedation in prepectoral subfascial position. Circulation 1997;95:946-950.
30. Bardy G, Raitt M, Jones G. Unipolar defibrillation systems. In: Singer I, ed. Implantable Cardioverter Defibrillator. Armonk, NY: Futura, 1994:365-376.
31. Herre J, Sauve M, Scheinman M. Long-term results of amiodarone therapy with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-449.
32. Olson P, Woelfel A, Simpson R, Foster J. Stratification of sudden death risk in patients receiving long-term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1993;71:823-826.
33. Weinberg B, Miles W, Klein L, Bolander J, Dusman R, Stanton M, Heger J, Langefeld C, Zipes D. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-120.
34. Sweeney M, Ruskin J, Garan H, McGovern B, Guy M, Torchiana D, Vlahakes G, Newell J, Semigran M, Dee G. Influence of the implantable cardioverter-defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995;92:3273-3281.
35. Kuck KH, Siebels J, Schneider M, Geiger M, and Hamburg Cardiac Arrest Study Group. Preliminary results of a randomized trial: AICD versus drugs (abstr). Rev Eur Tech Biomed 1990;12:110.
36. Siebels J, Cappato R, Rüppel R, Schneider M, Kuck KH, and the CASH Investigators. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993;72:109F-113F.